EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 8
Issue: 6
489-499
Year: 2021

EMERGING THERAPY FOR DENGUE

Debasmita Mukherjee*, Dr. Falguni Patra and Dr. Beduin Mahanti

School of Pharmacy, Techno India University, EM-4, EM Block, Sector V,Bidhannagar, Kolkata, West Bengal 700091.

***Corresponding Author: Debasmita Mukherjee**
School of Pharmacy, Techno India University, EM-4, EM Block, Sector V,Bidhannagar, Kolkata, West Bengal 700091.

Article Received on 21/04/2021 **Article Revised on 11/05/2021** **Article Accepted on 01/06/2021**

ABSTRACT
Dengue fever, commonly known as break bone fever is a flu-like illness caused by the Dengue virus. Dengue, a vector born viral fever caused by the various stain of flavivirus and transmitted by female Aedes mosquitoes , remain a therapeutically challenging disease despite various antiviral drug (ribivirin, glycyrrhizin, and 6-aziridine)are under evaluation , its severity is more pronounced in immune -compromised patients , also presents with Dengue fever sequel as dengue hemorrhagic fever and Dengue hemorrhagic shock. Each serotype is sufficiently different that there is no cross- protection and epidemics caused by multiple serotypes can occur. However, several classes of agents are in under investigation as potential anti- dengue drugs, including direct host modulators, antiviral, and RNAi therapeutics. Dengue is caused by the Dengue virus (DENV). DENV is a single-stranded RNA positive -strand virus. The serotype is sufficiently different thet there is no cross-protection and epidemics caused by multiple serotypes can occur. The incidence of dengue has grown around the world in recent a period often years. Treatments, causes, anti dengue drugs in development will be reviewed here.

KEYWORDS: Aedes Mosquito, Dengue Virus, Febrole, Epidemic, Serotype, Treatment, Homorrhagic, Vector, Flu.

INTRODUCTION
Dengue fever, commonly known as break bone fever is a flu-like illness caused by the Dengue virus. It is caused when an Aedes mosquito carrying the virus bites a healthy person. This disease is mainly found in the tropical and sub-tropical regions of the world. According to WHO, an estimated 500,000 people require hospitalization each year. Most cases occur in tropical areas of the world, with the America most susceptible to the disease. As per the data released by the Directorate of the National Vector Borne Disease Control Programme (NVBDCP), there have been 67,000 cases of Dengue fever as of 13th October 2019 in India. Scientists have also made a claim that Dengue is going to be the emerging disease of the world. Dengue has the most important abvoviral infection world with more than 30 millions. Dengue fever estimated to occur each year. Dengue viruses are arthropod its born viruses (arboviruses) in the genus Flavivirus (Family flaviviradae) with the positive polarity. Single–stranded RNA. is utilized Aedes (stegomyia) spp primarily. Albopictus as vector for domatic and peridomasti transmission And arboreal Aedes vector for enzootic transmission of the flavivirus genus including other important pathogens such as yellow fever. Dengue viruses are the causative agent of dengue fever. Its genome is about 11000 bases that the codes for three structural proteins (Membrane protein M, capsid protein C and envelop protein E) and seven nonstructural proteins itis also including the short non-coding reign on both the 5 and 3 ends. The dengue virus genome is 11644 nucleotides in length and is composed of three structural protein genes encoding the core protein (C),), an envelope protein (E), a membrane-associated protein (M), and seven nonstructural protein (NS) genes. Non-structural proteins are enveloped by glycoprotein, NS1 is of diagnostic and pathological importance. It is a 45 kDa in size and associated with viral haemagglutination and neutralization activity.



HISTORY

This disease was first described 1780, and the virus was isolated by Sabin 1944. Dengue virus infection is the most common arthopod- borne disease worldwide with an increasing incidence in the tropical regions of Asia, Africa and Central and South America. In the 18th century, dengue has caused repeated epidemics worldwide.

H. Graham in 1903 implicated *Aedes egypti* as the vector for the disease and the virus was isolated in 1944 by Albert Sabin et al.Dengue haemorrhagic fever gained nosologic status in 1954 and subsequently its became a endemic in many areas of tropical Asia. The first record of a case of probable dengue fever is in a Chinese medical encyclopaedia from the JinDynasty (265–420 AD) which referred to a "water poison" associated with flying insects. The primary vector, A. aegypti, spread out of Africa in the 15th to 19th centuries due in part to increased globalization secondary to the slave trade. There have been descriptions of epidemics in the 17th century, but the most plausible early reports of dengue epidemics are from 1779 and 1780, when an epidemic swept across Asia, Africa, and North America. From that

time until 1940, epidemics were infrequent. In 1906, transmission by the Aedes mosquitos was confirmed, and in 1907 dengue was the second disease (after yellow fever) that was shown to be caused by a virus. Further investigations by John Burton Cleland and Joseph Franklin Silver completed the basic understanding of dengue transmission. The marked spread of dengue during and after the Second World War has been attributed to ecologic disruption. The same trends also led to the spread of different serotypes of the disease to new areas and the emergence of dengue hemorrhagic fever. This severe form of the disease was first reported in the Philippines in 1953; by the 1970s, it had become a major cause of child mortality and had emerged in the Pacific and the Americas. Dengue hemorrhagic fever and dengue shock syndrome were first noted in Central and South America in 1981, as DENV-2 was contracted by people who had previously been infected with DENV-1 several years earlier. The term break-bone fever was applied by physician and United States Founding Father Benjamin Rush, in a 1789 report of the 1780 epidemic in Philadelphia. In the report title he uses the more formal term "bilious remitting fever". The term dengue fever came into general use only after 1828. Other historical terms include "breakheart fever" and "la dengue". Terms for severe disease include "infectious thrombocytopenic purpura" and "Philippine", "Thai", or "Singapore hemorrhagic fever".

Dengue in International Travel

Dengue is a leading public health problem with an expanding global burden. Dengue virus is also a significant cause of illness in international travellers with an increasing number of cases of dengue fever identified in travellers returning from dengue- endemic countries. This review focuses on the clinical illness of dengue infection in international travellers and provides a summary of the risk of infection for travellers, clinical features of infection, and an overview of dengue vaccines and their potential applicability to travellers where limited laboratory facilities exist, to developed countries with laboratories that can identify virus serotypes. Access to research facilities makes it possible to obtain more detailed information about a virus, including serotypes and even sequencing, when that information would be valuable. Systematic collection of clinical specimens and banking of serum or isolates may have future benefits as new technologies become available. From the data collection longitudinally over a decade by the GeoSentinel Surveillance Network. it was possible, for example, to examine month-by-month morbidity from a sample of 522 cases of dengue as a proportion of all diagnoses in 24 920 ill returned travellers seen at 33 surveillance sites. Travel-related dengue demonstrated a defined seasonality for multiple regions (South-East Asia, South Central Asia, Caribbean, and South America).

Dengue Feaver



Dengue fever (DF) and its severe forms dengue hemorrhagic fevers (DHF) and dengue shock syndromes (DSS) have become major international public health concerns. Dengue is the most prevalent arthropod-borne viral illness in humans, with the half of the world population at risk for infection and up to 50 million cases of dengue estimated each year. Dengue fever is also known as break bone fever is a mosquito borne tropical disease it's caused by the dengue viruses. The dengue has transmitted by the several species of mosquito the genus isAedes, The virus has five different types, and usually it gives long-lifeimmunity to that type but only short-term immunity to the other subsequent infection with a different types increase the risk of severalcomplication.

Causes

Dengue is caused due to four viruses, namely - DENV-1, DENV-2, DENV-3, and DENV-4. The virus enters a mosquito when it bites an already infected person. And the illness is spread when it bites a healthy person, and the virus spreads through the person's bloodstream.

Once a person recovers, he is immune to the specific virus and not the other three types. The probability of developing severe Dengue fever, also known as Dengue Haemorrhagic Fever, increases if you're infected a second, third or fourth time.

Spread



Dengue cannot be spread directly from person to person. However, a person infected and suffering from dengue fever can infect other mosquitoes. Humans are known to carry the infection from one country to another or from one area to another during the stage when the virus circulates and reproduces in the blood system. The Dengue virus is present in the blood of the patient. Sufferingfrom Dengue fever. Whenever an aedesmosquitoes bites a patient of dengue fever, it sucks blood and, the dengue virusis enters into its body. The virus undergoes further development of in the body of the mosquito for a few days. When the virus containing mosquito bites a normal human being (Healthy person), the virus is injected into the Healthy person body and he/she becomes infected and can developthe symptoms of dengue fever.

Complications

If severe, infectious disease will harm the lungs, liver, or heart. the vital signs will drop to dangerous levels, inflicting shock and, in some cases, death.

- Fluid overload.
- Post-viral fatigue syndrome.
- Myocarditis.
- Hepatitis.
- Acalculous inflammation.
- Acute metabolic process distress syndrome.
- Hepatic neurological disorder.
- Acute rubor.
- Hemophagocytic syndrome**.**
- How is that the infectious disease virus.

Symptoms

Primary symptoms of dengue appear three to 15 days after the mosquito bite and include high fever and severe headache, with severe pain behind the eyes that is apparent when trying to move the eyes. Other associated symptoms are joint pain, muscle and bone pain, rash, and mild bleeding.

- Severe Headache, Pains in muscles and joints.
- Pain behind the eyeballs especially on pressing the eyes or on moving the eyeballs.
- Sudden onset of high fever with feeling of chills (“Thandi Lagna”).
- Loss of appetite, feeling of nausea.
- Change in taste sensations in mouth.
- Mild pain in throat.
- Rash on the skin.

Life cycle

Until a few hundred years ago dengue virus itwas transmitted in sylvatic cycle’s inthe Asia and Africa between mosquitoes of the genus Aedes and non-human primates with rare emergences intothe human population.[5] The global spread of dengue virus, has followed its emergence from sylvatic cycles and the primary life cycle now exclusively involves transmission between humans and Aedes mosquitoes.



Life Cycle of mosquito

Aedes aegypti might be a alleged metamorphic insect. this suggests that the insects bear a whole metamorphosis with Associate in Nursing egg, larvae, pupae, and adult stage. The adult generation can vary from a try of weeks to a month looking forward to environmental conditions. The life cycle of mosquito could also be completed among one and a zero.5 to 3 weeks.



- ***EGG***

Mosquito mosquitos manufacture on the typical 100 to 2 hundred eggs per batch and manufacture 5 batches of eggs throughout a period. Eggs unit ordered on damp surfaces in areas apparently to concisely flood, like tree holes and artificial containers like barrels, drums, jars, pots, buckets, flower vases, plant saucers, tanks, discarded bottles, tins, tires, device, etc. and tons plenty of places where rain-water collects or is keep. Eggs will most often be placed at variable distances on high of the

water level. the female dipterous insect will not lay the entire clutch at one web site but rather unpleated the eggs over several sites. The eggs unit swish, long, ovoidshaped, and roughly one metric long measure long. ordered eggs can survive for very long periods throughout a dry state, generally for quite an year. However, they hatch instantly once submerged in water. Thismakes the management of the communicable disease virus dipterous insect very difficult .

- **Larvae**

Once hatching of the eggs, the larvae kill organic stuff among the water, like microorganism and totally different microscopic organisms. Most of the larval stage is spent at the water's surface, tho' they go to swim to all-time low of the instrumentation if disturbed or once feeding. Larvae unit generally found around the zero in puddles, tires, or among any object holding water. Larval development is temperature-dependent. The larvae bear four instars, payment a short amount of some time among the first three, and up to some days among the fourth invertebrate. Fourth invertebrate larvae unit concerning eight millimeters long. Males develop faster than females, therefore males typically get earlier. If temperatures unit cool, mosquito can keep among the larval stage for months aloha as a result of the water is good.

- **Pupae**

Once the fourth invertebrate, the larvae enter the immature stage. dipterous insect pupae unit mobile and answerstimuli. Pupae do not feed and take concerning a pair of days to develop. Adults emerge by ingesting air to expand the abdomen therefore gruff open the immature case and emerge head first.

Mechanism

When a dipterous insect carrying communicable disease virus bites a personal, the virus enters the skin at the side of the mosquito's secretion. It binds to and enters white blood cells, and reproduces among the cells whereas they move throughout the body. The white blood cells respond by producing several signal proteins, like cytokines and interferons, that unit accountable for many of the symptoms, just like the fever, the flu-like symptoms, and conjointly the severe pains. In severe infection, the virus production among the body is greatly increased, and much of plenty of organs (such as a result of the liver and conjointly the bone marrow) could also be affected. Fluid from the blood leaks through the wall of small blood vessels into body cavities because of capillary porosity. As a result, less blood circulates among the blood vessels, and conjointly the pressure becomes therefore low that it cannot give good blood to important organs. moreover, pathology of the bone marrow because of infection of the stromal cells finishes up in reduced numbers of platelets, that unit necessary for effective blood clotting; this may increase the danger of trauma, th**e** alternative major complication of breakbone fever.

Methods of bioanalysis for anti-dengue activity

Pre-clinical

Dengue it is a positive stranded RNA virus with an 11kb genome, encoding a polyprotein precursor cleaved to generate at least 10 proteins, including three structural proteins (core, membrane associated protein, and envelope protein), and seven nonstructural proteins (NS1, NS2a, NS2b, NS3, NS4b, NS5). DENV is transmitted by silent, urban mosquito vectors. Including A. albopictus and Aedesaegypti,A. polynesiensisand A. scutellaris, to man. Other modes of transmission include via blood products, vertical transmission and organ transplant.In man, the initial cellular target of dengue is thought to be dendritic cells, followed by lymphatic spread and then distribution to macrophages and monocytes. The full host of cells infected in vivoremain a subject of investigation, but may also include hepatocytes, myocytes, and other cell types.

***Clinical*:** Clinical methods for evaluation of anti-dengue effects are development. A major hurdle facing DENV clinical trials is the need for establishment of accurate diagnostic testing for case identification. The current diagnostics for DENV available in the US and other high resource countries (IgM and IgG ELISA, PCR) are limited by a requirement for skilled workers, specialized and refrigeration, equipment .Current point- of-care (POC) diagnostic tests for DENV. Based on lateral flow detection of secreted IgMand DENVNS1 protein in plasma/serum/blood or saliva IgA.

Treatment

Agents in development for anti-dengue activity

Direct-acting antiviral glycoside analogs

Corticosteroids

While some studies report that corticosteroids square measure effective in dengue fever infection, a lot of proof is needed before they're suggested.[23,24] One irregular controlled trial found that the employment of oral Liquid Pred throughout the first acute part of dengue fever infection wasn't related to prolongation of viraemia or alternative adverse effects. though not high-powered to assess effectivity, the study found no reduction within the development of shock or alternative recognized complications of dengue fever viral infection.

Statins

Statins have pleiotropic effects that improve epithelium perform. These effects are postulated to enhance the severe manifestations of dengue fever, that square measure partly thanks to inflammatory processes that have an effect on the tube epithelium. One irregular controlled trial found that, whereas statin was safe and well- tolerated in patients with dengue fever, there was no proof of a helpful result. Others square measure explained in short within the below section of the treatment.

BP13944
A screen of sixty,000 chemical compounds in an exceedingly DENV serotype a pair of luciferase harboring replicon (BHK-21 cells). Itis recently known BP13944, a quaternary ammonia salt, as Associate in Nursing NS3antiviral drug.

RNA dependent ribonucleic acid enzyme (NS5) inhibitors
N-sulfonylanthranilic acid derivatives were known as DENV RdRp inhibitors through screening of 1 million compounds. The known hit was found to bind DENV NS5 at the positioning of the doorway to the ribonucleic acid tunnel. whereas this specific compound isn't below more development, the idea of inhibiting enzyme through the tunnel likewise as alternative allosteric pockets is being pursued.

Nucleoside analogues
Balapiravir (RG1626) is a prodrug of a nucleoside analog, R1479, which it must be triphosphorylated for conversion into active form. Balapiravir was initially developed for the treatment of HCV, but clinical trials were stopped due to toxicity during extended treatment courses (2-3 months) in combination with pegylated interferon and ribavirin. Because R1479 displayed in vitro anti dengue activity, and because of the shorter projected treatment duration for acute dengue infection (limiting toxicity), anti-dengue .

***α*-keto amides**
Electrophilic entice for the aminoalkanoic acid element of the DENV NS2b-NS3 aminoalkanoic acid peptidase, and have known known amides as DENV peptidase inhibitors.

Protease (NS2b-NS3) inhibitors
Recombinant retrocyclin one. Rothan et al. created recombinant NS2B-NS3 peptidase in E. coli and known recombinant retrocyclin one, a ion cyclic amide letter of the alphabet defensive analog with anti-HIV activity. A potent DENVprotease matter.

Antiviral medicine
The development of a secure and effective medication that's active against the dengue fever virus may be a priority. though this has been tried, presently there are no prosperous outcomes.[26] Balapiravir may be a prodrug of a glycoside Associate in Nursingalog (R1479) and an matter of viral hepatitis virus replication in vivo. it absolutely was found to be ineffective as a candidate drug in an exceedingly irregular, double-blind placebocontrolled trial of balapiravir in adult patients with dengue fever.[27] Balapiravir (RG1626) may be a prodrug of a glycoside analog, R1479, that it should be triphosphorylated for conversion into the active kind. Balapiravir was at first developed for the treatment of HCV, however clinical trials were stopped thanks to toxicity throughout extended treatment courses (2-3 months) together with pegylated antiviral drug and antiviral drug. as a result of R1479 displayed in vitro antidengue activity, and since of the shorter projected treatment length for acute dengue fever infection (limiting toxicity), anti-dengue effects of balapiravir were explored in trial|phase II|clinical trial|clinical test} clinical trial.

Quinoline containing compounds
Using virtual screening for DENV peptidase inhibitors followed by scaffold hopping, to expand chemical diversity, then a DENV luciferase newsperson replicon assay, Deng et al. have delineate seventeen new compounds with NS2b-NS3 antiviral drug activity, which may currently function potential lead structures for more discovery efforts.

Ribavirin
Ribavirin could be a broad-acting matter of polymer and RNA viruses. it's an artificial nucleoside analog that inhibits inosine monophosphate dehydrogenase with ensuing GTP pool depletion however has multiple extra planned mechanisms of action, as well as antiviral genes. antiviral drug use has been restricted by the toxicity of each oral formulations and gaseous, decreasing its clinical effectiveness .

NS4b matter
Van Cleef et al. recently screened the office Clinical assortment of a drug-like little molecule for anti-DENV activity in Hela cells harboring a subgenomic DENV2-replicon newsperson and known the newsperson opioid receptor antagonist SDM25N as potent DENV matter .

Translation inhibitors
A high outturn screen for reduction or elimination of DENV CPE and known benzomorphan compounds that inhibit DENV through suppression of ribonucleic acid translation and conjointly inhibit DENV viraemia in mice, tho' higher doses were restricted by toxicity.

Methyltransferase (NS5) inhibitors
Using a fragment-based drug discovery approach, recently screened five hundred drug-like fragments by thermal-sift assay for binding to the DENV NS3 helicase or NS5 methyltransferase, and known seven valid MTase binders, every containing 5-6 ten-membered aromatic rings.

NS4b inhibitor
Van Cleef et al. recently screened the NIH Clinical Collection of drug-like small molecule for anti-DENV activity in HeLa cells harboring a sub genomic DENV2-replicon reporter and identified the δ opioid receptor antagonist SDM25N as potent DENV inhibitor.

Capsid matter
A high output tiny molecule screen with a readout of DENV induced CPE was performed on over two hundred, 000compounds and known ST-148 as a singular matter of the DENVcapsid macromolecule with

each in vitro and in vivo effects (AG129 mice).

Peptide inhibitors of varied denv proteins

Several teams have recently planned the utilization of amide inhibitors to dam DENV infection. for instance, they have known the mimetic amide DN59, that corresponds to a locality of the dengue fever virus envelope macromolecule, as associate degree matter of all four serotypes of dengue fever virus. Host modulators This property in tries to inhibit infectious agent replication through deprivation of those needed host factors, or dependency factors. This strategy, targeting host factors to impede dengue fever virus infection.

Lovastatin

Statins square measure inhibitors of 3-hydroxy-3-methylglutaryl molecule A(HMG-CoA) enzyme, used for the lipid-lowering and mortality reduction into the disorder, and have a superb safety profile. Statins are found to exhibit anti-DENV properties in each cellculture and mouse models. A trial examining the protection and antiviral properties of lipid-lowering medication in adult patients is currently current in Vietnam.

Vitamin D

Treatment of each monocytic (U937) and internal organ cells with internal organ, 25dihydroxy-vitamin D3 was related to shriveled levels of DENV infection.

Viral detector (RIG-I and TLR3) agonists

The innate system includes the detection of infectious agent RNA by the helicase domain of RIG-I. an artificial 5' triphosphate (5'ppp) RNA was designed to stimulate this host innate response as associate degree opposingviral therapeutic and was found to own anti DENV effects once transfected into A549 cells moreover as primary human monocytes before DENV infection.

Interferon

The type one IFNs it's, as well as the as well as, square measure among the broadest acting associate degreetiviral IFNα could be a current element of an anti-HCV medical care and has additionally been used for hepatitis B, severe acute metastasis syndrome, and Severe virus infection is that the results of subversion of the host response, rendering that response ineffective. a significant commonpathway of infectious agent it's associate degree immune escape is that the suppression of the as well as pathway. whereas IFN mechanisms vary from virus to virus, activation of IFN effectors downstream of infectious agent subversion. might establish the common drug targets for the restoration of an efficient host antiviral response. though it'll be doable to cut back reliance on as well as in HCV treatment regimens, understanding the mechanism of this broad-acting antiviral can inform the look of agents active against several viruses, like DENV, that antagonize IFNα and that no current treatment square measure offered.

IEG activation can circumvent infectious agent subversion of IFN signal

In general, IFNα will with success inhibit the DENV if given preinfection, however not post-infection, and thanks to DENV mediate suppression of early members of the IFN signal pathway, although some antiviral result was determined in post-infection administration of PEGrIFN-alpha-2a, that considerably down daily viraemia levels and improved virus clearance, within the macaque. process wherever viruses block or the host IFN response will inform the look of antivirals that acts downstream of that block. In preliminary studies, we've to spot one hundred twenty host antiviral candidates in an exceedingly whole-genome siRNA screen for HCV IEGs.



Figure 5: IEG activation will circumvent viral subversion of IFN signaling.

D4 Intropin receptor antagonists
Classes of tricyclic antidepressant drug little molecule compound, the dihydro benzo thiepines (DHBTs), during a high turnout little molecule screen for the DENV-2 inhibitors, use high content immune-fluorescent assay readout in HEK293T cells. The any determined that SKI417616, a extremely active DHBT, smothered all four DENV serotypes in vitro at associate early event within the DENV lifecycle, and known the mechanism of activity as host D4 Intropin receptor inhibition.

Pentoxifylline
A small run of the TNFa inhibitors, drug is showed a possible decrease in mean length of unit keep and shrunken TNFa levels, although infectious agent parameters weren't assessed.

Ivermectin
The associateti-helminthic drug ivermectin has been known as an substance of the nuclear businessperson import in α/β. as a result of DENV NS5polymerase activity needs import in α/β, anti-viral properties of ivermectin were explored, and it's discovered that pretreatment with ivermectin smothered DENV infection of Vero cells.

Chloroquine
Chloroquine is an affordable, well-tolerated lysosomotropic 4amino-quinoline spinoff, that is renowned as associate anti-malarial drug however additionally possesses in vitro anti-viral activity, as well as anti-DENV activity, probably associated with its impact of skyrocketing endosomal. Therapeutic plasma concentration is within the vary of 15- 30ng/ml.

Amodiaquine
The quinoline spinoff amodiaquine was recently known during a replicon supported a screen for anti-DENV agents, and it's confirmed to own anti-DENV activity in DENV2 plaque assays and qRT PCR for each intracellular and living thingDENV levels.

RNAi
RNA interference may be a cistron silencing method. that degrades the target polymer during a sequence-specific fashion. RNAihasto has been projected as a technique to directly inhibit infectious agent infections, as well as the DENV. One cluster showed the employment of nerve fiber cells targeting peptide-mediated delivery of siRNA against a preserved sequence within the DENV envelope effectively suppressed DENV replication in macrophages and monocytes. additionally to the RNAi mediate suppression of the DENV itself, RNAi-mediated suppression of infectious agent dependency factors, or issue is needed by the virus for productive infection, has been shown to inhibit DENV. There ar presently no RNAi agents registered underneath clinical trials. Gov. once searched with dandy fever.

Morpholinos
Taking advantage of RNA–protein interactions needed for the DENV replication, antisense peptide-conjugated phosphorodiamidate morpholino oligomers (P-PMOs) are designed to sterically interfere with these interactions.

Amodiaquine
The quinoline spinoff amodiaquine was recently known during a replicon supported a screen for anti-DENV agents, and it's confirmed to own anti-DENV activity in DENV2 plaque assays and qRT PCR for each intracellular and living thingDENV levels.

Other compounds
Other agents that are advised to a shoantibiotic, that has been found to own the distinctive property, among aminoglycosides, of inhibiting DENV and FCI 106, a compound of unknown mechanism known during a screen for anti- Ebola agents, that has additionally been found to own anti-DENV activity, in DC-SIGN cells .

Medicinal plant derivatives
There is a major quantity of analysis dedicated to a hypothesis-driven and practice-based identification of present compounds with the anti-dengue properties. it's vital to notice that a lot of the compounds examined in these studies ar chosen as a result of they're already in use against dandy fever in ancient settings, underscoring the requirement to look at their impact on dengue-related outcomes, in spite of whether or not they are going to be assessed for drug development. w anti-dengue activity as well as genetic in, associate aminoglycoside levels.

CONCLUSION
Dengue is emerging as worldwide threat and is pressing public health priority in several countries. The Government and the pharmaceuticals industries have been taking initiative to develop ne strategies to improve the diagnosis and treatment of Dengue virus . The challenge here lies in however effectively the methods developed are place into use. There also a an obligatory need to globalize awareness and preventive measures among the plenty so as to regulate the incidence. Combined efforts of the health care industries, governing bodies, and efforts at indivudual level would facilitate America and also help us to handle the prevalence of dengue fever.

ACKNOWLEDGEMENT
The success and final outcome of this project a lot of guidance and assistance and I am very thankful to Dr. Falguni Patra for guiding me all through the project work and giving me clearconcept about this topic and making my project appreciable.

I have a clean and perfect idea about this topic I have covered in the project.

REFERENCES

1. IA Zybert, Rodenhuis, J Wilschut, JMSmit."Dengue virus life cycle: viral PMID 20372965, 2010.
2. TP Endy, SC Weaver, KA Hanley. Dengue virus: past, present and future In: Frontiers in dengue virus research. KA Hanley, SC Weaver. eds. Caister Academic Press: Norfolk, UK ISBN 978-1-904455; 2010; 50-9.
3. DJ Gubler. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem inthe 21st century. Trends Microbial, 2002; 10: 100–3.
4. Suaya JA, Shepard DS, Siqueira JB, et al. Cost of Dengue cases in eight countries in the Americas and Asia: a prospective study, Am J Trop Med Hyg, 2009; 80: 846-55.
5. EC Holmes, SS Twiddy. The origin, emergence and evolutionary genetics of dengue virus. Infection GeneticsEvolution, 2003; 3: 19–28
6. DJ Gubler. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem inthe 21st century. Trends Microbial, 2002; 10: 100-3.
7. Ferri FF. Dengue fever. In: Ferri's Clinical Advisor 2017. Philadelphia, Pa.: Elsevier; 2017. https://www.clinicalkey.com. Accessed June 10, 2017.
8. https://www.webmd.com/a-to-z-guides/dengue-feverreference.
9. www.mayoclinic.org/diseases-conditions/denguefever/symptoms-causes/syc-20353078.
10. Thein S, Aung MM, Shwe TN, et al. Risk factors in dengue shock syndrome, Am J Trop Med Hyg, 1997; 56: 566-72.
11. Sangkawibha N, Rojanasuphot S, Ahandrik S, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak, Am J Epidemiol, 1984; 120: 653-69.
12. https://diseasesdic.com/dengue-complications-riskfactors-diagnosis/.
13. W.H.O. Dengue: guidelines for diagnosis, treatment, prevention and control. WHO/HTM/NTD/DEN/2009.1. World Health Organization, 2009.
14. Brady Oj, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus.PLoS Negl. Trop. Dis., 2012; 6: e1760.
15. IA Zybert, Rodenhuis, j Wilschut, JM Smit." Dengue Virus Life Cycle: viral PMID 20372965, 2010.
16. Dengue Virus Net. "Aedes aegypti." Dengue transmission by Aedes aegypti mosquito, 2011.
17. Rodhain, F., & Rosen, L. "Mosquito Vectors and Dengue Virus-Vector Relationships." In Dengue and Dengue Hemorrhagic Fever, eds. D. J. Gubler & G. Kuno (Cambridge: CABI, 2001; 45–60.
18. Symptoms and what to do if you think you have dengue. Centers for Disease Control and Prevention. https://www.cdc.gov/dengue/symptoms/index.html. Accessed June 10, 2017.
19. Kuldeep Singh, Pragati Shakya. Prevention and control of dengue by herbal remedies. J Chem Pharm Res https://www.who.int/westernpacific /healthtopics/dengue, 2016; 8: 708-13.
20. Dengue Virus Net. "Aedes aegypti." Dengue transmission Prevention, 2011.
21. Fusco DN, Chung RT. Review of current dengue treatment and therapeutics in development. J Bioanal Biomed 2014; S8: 1-10. edition. Geneva: WHO, 2008.
22. Blacksell SD. Commercial dengue rapid diagnostic tests for point-of-care application: recent evaluations and future needs?, 23.
23. Rajapakse S. Corticosteroids in the treatment of dengue illness. Trans R Soc Trop Med Hyg. 2009; 103: 122-126.
24. Zhang F, Kramer CV. Corticosteroids for dengue infection. Cochrane Database Syst Rev. ,2014; (7): CD003488.
25. Tam DT, Ngoc TV, Tien NT, et al. Effects of shortcourse oral corticosteroid therapy in early dengue 26.infection in Vietnamese patients: a randomized,World Health Organization. The World Health Report fighting disease, fostering development. Geneva: WHO, 1996; 137.
26. World Health Organization. International Health Regulations. 2nd
27. Fusco DN, Chung RT. Review of current dengue treatment and therapeutics in development. J Bioanal Biomed 2014;S8:1-10.edition. Geneva: WHO, 2008.
28. Blacksell SD. Commercial dengue rapid diagnostic tests for point-of-care application: recent evaluations and future needs? J Biomed Biotechnol, 2012; 15: 1967. http://dx.doi.org/10.1155/2012/151967
29. Niyomrattanakit P, Chen YL, Dong H, Yin Z, Qing M. Inhibition of dengue virus polymerase by blockingof the RNA tunnel. J Virol, 2010; 84: 5678-86.
30. Brandl M, Wu X, Holper M, Hong L, Jia Z. Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability. Drug Dev Ind Pharm, 2008; 34: 683-91.
31. Yang CC, Hu HS, Wu RH, Wu SH, Lee SJ. A novel dengue virus inhibitor, BP13944, discovered by high- throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease.Antimicrob Agents Chemother, 2014; 58: 110-9.
32. Krishnan MN, Garcia-Blanco MA2. Targeting host factors to treat West Nile and dengue viral infections.Viruses, 2014; 6: 683-708.
33. Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir ChemChemother, 2012; 23: 1-12.
34. Frias Staheli N, Dorner M, Marukian S, Billerbeck E, Labitt RN.Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug

testing. J Virol, 2014; 88: 2205-18.
35. Fusco DN, Brisac C, John SP, Huang YW, Chin CR. A genetic screen identifies interferon-Î±effector genes required to suppress hepatitis C virus replication. Gastroenterology, 2013; 144: 1438-1449, 1449.
36. Yang CC, Hu HS, Wu RH, Wu SH, Lee SJ. A novel dengue virus inhibitor, BP13944, discovered by high- throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease. Antimicrob Agents Chemother, 2014; 58: 110-9.
37. Coutard B, Decroly E, Li C, Sharff A, Lescar J. Assessment of dengue virus helicase and methyltransferase as targets for fragment-based drug discovery. Antiviral Res., 2014; 106: 61-70.
38. AbdKadir SL, Yaakob H, Mohamed Zulkifli R. Potential antidengue medicinal plants: a review. J Nat Med, 2013; 67: 677-89.